NO309190B1 - Neurobeskyttende kromanforbindelser og farmasöytisk blanding - Google Patents

Neurobeskyttende kromanforbindelser og farmasöytisk blanding Download PDF

Info

Publication number: NO309190B1
Authority: NO; Norway
Prior art keywords: hydroxy; fluorophenyl; piperidin; chroman; acid
Prior art date: 1994-01-31

Application number

NO963186A

Other languages

English (en)

Norwegian (no)

Other versions

NO963186D0 (no

NO963186L (no

Inventor

Todd W Butler

Bertrand Leo Chenard

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-01-31

Filing date

1996-07-30

Publication date

2000-12-27

1996-07-30 Application filed by Pfizer filed Critical Pfizer

1996-07-30 Publication of NO963186D0 publication Critical patent/NO963186D0/no

1996-07-30 Publication of NO963186L publication Critical patent/NO963186L/no

2000-12-27 Publication of NO309190B1 publication Critical patent/NO309190B1/no

Links

230000000324 neuroprotective effect Effects 0.000 title claims description 12
239000008194 pharmaceutical composition Substances 0.000 title description 3
150000001845 chromium compounds Chemical class 0.000 title 1
150000003839 salts Chemical class 0.000 claims abstract description 15
JQQWDYJWDCIVKQ-QUCCMNQESA-N (3r,4s)-3-(4-benzyl-4-hydroxypiperidin-1-yl)-3,4-dihydro-2h-chromene-4,7-diol Chemical compound C1CN([C@H]2[C@H](C3=CC=C(O)C=C3OC2)O)CCC1(O)CC1=CC=CC=C1 JQQWDYJWDCIVKQ-QUCCMNQESA-N 0.000 claims abstract description 12
150000001875 compounds Chemical class 0.000 claims description 51
239000000203 mixture Substances 0.000 claims description 20
239000003937 drug carrier Substances 0.000 claims description 5
230000003287 optical effect Effects 0.000 claims description 3
IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims 1
229940095064 tartrate Drugs 0.000 claims 1
238000011282 treatment Methods 0.000 abstract description 17
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 10
239000003814 drug Substances 0.000 abstract description 9
201000010099 disease Diseases 0.000 abstract description 8
229940079593 drug Drugs 0.000 abstract description 7
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract description 3
HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 abstract description 3
230000000903 blocking effect Effects 0.000 abstract description 3
239000003795 chemical substances by application Substances 0.000 abstract 1
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 26
238000000034 method Methods 0.000 description 21
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
229910001868 water Inorganic materials 0.000 description 15
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 13
238000004458 analytical method Methods 0.000 description 13
238000006243 chemical reaction Methods 0.000 description 13
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
229930195712 glutamate Natural products 0.000 description 11
238000005481 NMR spectroscopy Methods 0.000 description 10
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
-1 dibromo compound Chemical class 0.000 description 10
230000000694 effects Effects 0.000 description 10
239000000243 solution Substances 0.000 description 10
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
239000005557 antagonist Substances 0.000 description 9
230000002461 excitatory amino acid Effects 0.000 description 9
239000003257 excitatory amino acid Substances 0.000 description 9
239000007787 solid Substances 0.000 description 9
239000001963 growth medium Substances 0.000 description 8
LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 8
239000002904 solvent Substances 0.000 description 8
239000002253 acid Substances 0.000 description 7
238000002844 melting Methods 0.000 description 7
230000008018 melting Effects 0.000 description 7
LVEILCHKSOKFCV-UHFFFAOYSA-N 4-(4-fluorophenyl)-1-(4-hydroxy-7-phenylmethoxy-3,4-dihydro-2h-chromen-3-yl)piperidin-4-ol Chemical compound C=1C=C2C(O)C(N3CCC(O)(CC3)C=3C=CC(F)=CC=3)COC2=CC=1OCC1=CC=CC=C1 LVEILCHKSOKFCV-UHFFFAOYSA-N 0.000 description 6
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 6
210000004027 cell Anatomy 0.000 description 6
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 5
102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 5
108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 5
230000002253 anti-ischaemic effect Effects 0.000 description 5
210000003169 central nervous system Anatomy 0.000 description 5
239000000047 product Substances 0.000 description 5
102000005962 receptors Human genes 0.000 description 5
108020003175 receptors Proteins 0.000 description 5
AAGXQJIDHYJVEG-UHFFFAOYSA-N 3,3-dibromo-7-phenylmethoxy-4h-chromen-2-one Chemical compound C1=C2OC(=O)C(Br)(Br)CC2=CC=C1OCC1=CC=CC=C1 AAGXQJIDHYJVEG-UHFFFAOYSA-N 0.000 description 4
208000024827 Alzheimer disease Diseases 0.000 description 4
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
208000009132 Catalepsy Diseases 0.000 description 4
208000023105 Huntington disease Diseases 0.000 description 4
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 4
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
241000700159 Rattus Species 0.000 description 4
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 4
206010047853 Waxy flexibility Diseases 0.000 description 4
229910052794 bromium Inorganic materials 0.000 description 4
210000001638 cerebellum Anatomy 0.000 description 4
230000002860 competitive effect Effects 0.000 description 4
239000000706 filtrate Substances 0.000 description 4
229960003878 haloperidol Drugs 0.000 description 4
239000000543 intermediate Substances 0.000 description 4
238000001953 recrystallisation Methods 0.000 description 4
239000000523 sample Substances 0.000 description 4
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
239000011975 tartaric acid Substances 0.000 description 4
235000002906 tartaric acid Nutrition 0.000 description 4
VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 3
102000018899 Glutamate Receptors Human genes 0.000 description 3
108010027915 Glutamate Receptors Proteins 0.000 description 3
108090000862 Ion Channels Proteins 0.000 description 3
102000004310 Ion Channels Human genes 0.000 description 3
208000012902 Nervous system disease Diseases 0.000 description 3
208000025966 Neurological disease Diseases 0.000 description 3
208000018737 Parkinson disease Diseases 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
208000006011 Stroke Diseases 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
239000000556 agonist Substances 0.000 description 3
230000027455 binding Effects 0.000 description 3
239000012267 brine Substances 0.000 description 3
239000000872 buffer Substances 0.000 description 3
239000007853 buffer solution Substances 0.000 description 3
ZOOGRGPOEVQQDX-UHFFFAOYSA-N cyclic GMP Natural products O1C2COP(O)(=O)OC2C(O)C1N1C=NC2=C1NC(N)=NC2=O ZOOGRGPOEVQQDX-UHFFFAOYSA-N 0.000 description 3
239000003085 diluting agent Substances 0.000 description 3
150000002148 esters Chemical class 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
229910052739 hydrogen Inorganic materials 0.000 description 3
230000001077 hypotensive effect Effects 0.000 description 3
230000001057 ionotropic effect Effects 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
208000015122 neurodegenerative disease Diseases 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
239000002002 slurry Substances 0.000 description 3
239000011734 sodium Substances 0.000 description 3
229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
235000017557 sodium bicarbonate Nutrition 0.000 description 3
239000012279 sodium borohydride Substances 0.000 description 3
229910000033 sodium borohydride Inorganic materials 0.000 description 3
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
239000007858 starting material Substances 0.000 description 3
238000012360 testing method Methods 0.000 description 3
231100000419 toxicity Toxicity 0.000 description 3
230000001988 toxicity Effects 0.000 description 3
ZQEBQGAAWMOMAI-SSDOTTSWSA-N (2r)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CCC[C@@H]1C(O)=O ZQEBQGAAWMOMAI-SSDOTTSWSA-N 0.000 description 2
UUDAMDVQRQNNHZ-UHFFFAOYSA-N (S)-AMPA Chemical compound CC=1ONC(=O)C=1CC(N)C(O)=O UUDAMDVQRQNNHZ-UHFFFAOYSA-N 0.000 description 2
SEBPXHSZHLFWRL-UHFFFAOYSA-N 3,4-dihydro-2,2,5,7,8-pentamethyl-2h-1-benzopyran-6-ol Chemical class O1C(C)(C)CCC2=C1C(C)=C(C)C(O)=C2C SEBPXHSZHLFWRL-UHFFFAOYSA-N 0.000 description 2
LQVAVQIGRCMWJQ-UHFFFAOYSA-N 3-[4-(4-fluorophenyl)-4-hydroxypiperidin-1-yl]-7-phenylmethoxy-3,4-dihydrochromen-2-one Chemical compound C1CC(O)(C=2C=CC(F)=CC=2)CCN1C(C(OC1=C2)=O)CC1=CC=C2OCC1=CC=CC=C1 LQVAVQIGRCMWJQ-UHFFFAOYSA-N 0.000 description 2
QXWRXWPNHLIZBV-UHFFFAOYSA-N 4-(4-fluorophenyl)piperidin-4-ol Chemical compound C=1C=C(F)C=CC=1C1(O)CCNCC1 QXWRXWPNHLIZBV-UHFFFAOYSA-N 0.000 description 2
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
UYNVMODNBIQBMV-UHFFFAOYSA-N 4-[1-hydroxy-2-[4-(phenylmethyl)-1-piperidinyl]propyl]phenol Chemical compound C1CC(CC=2C=CC=CC=2)CCN1C(C)C(O)C1=CC=C(O)C=C1 UYNVMODNBIQBMV-UHFFFAOYSA-N 0.000 description 2
GPJCOQPUQUEBTB-UHFFFAOYSA-N 7-hydroxy-3,4-dihydrochromen-2-one Chemical compound C1CC(=O)OC2=CC(O)=CC=C21 GPJCOQPUQUEBTB-UHFFFAOYSA-N 0.000 description 2
RZOSDJYQUKVYOO-UHFFFAOYSA-N 7-phenylmethoxy-3,4-dihydrochromen-2-one Chemical compound C1=C2OC(=O)CCC2=CC=C1OCC1=CC=CC=C1 RZOSDJYQUKVYOO-UHFFFAOYSA-N 0.000 description 2
208000030507 AIDS Diseases 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
DRGRNZNAINBHBS-QAZHXLKKSA-N CCO.OC(C(C(O)=O)O)C(O)=O.O[C@H]([C@@H](COC1=C2)N(CC3)CCC3(C(C=C3)=CC=C3F)O)C1=CC=C2O.O Chemical compound CCO.OC(C(C(O)=O)O)C(O)=O.O[C@H]([C@@H](COC1=C2)N(CC3)CCC3(C(C=C3)=CC=C3F)O)C1=CC=C2O.O DRGRNZNAINBHBS-QAZHXLKKSA-N 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 2
RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
241000283073 Equus caballus Species 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
206010019233 Headaches Diseases 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
208000019695 Migraine disease Diseases 0.000 description 2
HOKKHZGPKSLGJE-UHFFFAOYSA-N N-methyl-D-aspartic acid Natural products CNC(C(O)=O)CC(O)=O HOKKHZGPKSLGJE-UHFFFAOYSA-N 0.000 description 2
208000002193 Pain Diseases 0.000 description 2
229930182555 Penicillin Natural products 0.000 description 2
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
ASNFTDCKZKHJSW-REOHCLBHSA-N Quisqualic acid Chemical compound OC(=O)[C@@H](N)CN1OC(=O)NC1=O ASNFTDCKZKHJSW-REOHCLBHSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
206010046543 Urinary incontinence Diseases 0.000 description 2
238000002835 absorbance Methods 0.000 description 2
239000002249 anxiolytic agent Substances 0.000 description 2
230000000949 anxiolytic effect Effects 0.000 description 2
238000009835 boiling Methods 0.000 description 2
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
229910052801 chlorine Inorganic materials 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
239000013078 crystal Substances 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
206010013663 drug dependence Diseases 0.000 description 2
206010015037 epilepsy Diseases 0.000 description 2
239000004060 excitotoxin Substances 0.000 description 2
239000012091 fetal bovine serum Substances 0.000 description 2
229910052731 fluorine Inorganic materials 0.000 description 2
239000008103 glucose Substances 0.000 description 2
235000013922 glutamic acid Nutrition 0.000 description 2
239000004220 glutamic acid Substances 0.000 description 2
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
231100000869 headache Toxicity 0.000 description 2
229910000042 hydrogen bromide Inorganic materials 0.000 description 2
229960003998 ifenprodil Drugs 0.000 description 2
238000011534 incubation Methods 0.000 description 2
239000012442 inert solvent Substances 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
239000012280 lithium aluminium hydride Substances 0.000 description 2
239000000463 material Substances 0.000 description 2
239000002609 medium Substances 0.000 description 2
206010027599 migraine Diseases 0.000 description 2
239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
229940049954 penicillin Drugs 0.000 description 2
JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
235000018102 proteins Nutrition 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
238000000746 purification Methods 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
229960005322 streptomycin Drugs 0.000 description 2
208000011117 substance-related disease Diseases 0.000 description 2
KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
239000000725 suspension Substances 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
210000001364 upper extremity Anatomy 0.000 description 2
YFYNOWXBIBKGHB-FBCQKBJTSA-N (1s,3r)-1-aminocyclopentane-1,3-dicarboxylic acid Chemical compound OC(=O)[C@]1(N)CC[C@@H](C(O)=O)C1 YFYNOWXBIBKGHB-FBCQKBJTSA-N 0.000 description 1
VOROEQBFPPIACJ-SCSAIBSYSA-N (2r)-2-amino-5-phosphonopentanoic acid Chemical compound OC(=O)[C@H](N)CCCP(O)(O)=O VOROEQBFPPIACJ-SCSAIBSYSA-N 0.000 description 1
MYDMWESTDPJANS-ZCFIWIBFSA-N (2r)-2-amino-7-phosphonoheptanoic acid Chemical compound OC(=O)[C@H](N)CCCCCP(O)(O)=O MYDMWESTDPJANS-ZCFIWIBFSA-N 0.000 description 1
IRJCBFDCFXCWGO-SCSAIBSYSA-N (2r)-2-azaniumyl-2-(3-oxo-1,2-oxazol-5-yl)acetate Chemical compound [O-]C(=O)[C@H]([NH3+])C1=CC(=O)NO1 IRJCBFDCFXCWGO-SCSAIBSYSA-N 0.000 description 1
ZQEBQGAAWMOMAI-ZETCQYMHSA-N (2s)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CCC[C@H]1C(O)=O ZQEBQGAAWMOMAI-ZETCQYMHSA-N 0.000 description 1
125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 1
LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
208000019901 Anxiety disease Diseases 0.000 description 1
201000006474 Brain Ischemia Diseases 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
206010008120 Cerebral ischaemia Diseases 0.000 description 1
229940127486 Competitive NMDA Receptor Antagonists Drugs 0.000 description 1
RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
ASNFTDCKZKHJSW-UHFFFAOYSA-N DL-Quisqualic acid Natural products OC(=O)C(N)CN1OC(=O)NC1=O ASNFTDCKZKHJSW-UHFFFAOYSA-N 0.000 description 1
206010012289 Dementia Diseases 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
108091006027 G proteins Proteins 0.000 description 1
102000030782 GTP binding Human genes 0.000 description 1
108091000058 GTP-Binding Proteins 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
208000013016 Hypoglycemia Diseases 0.000 description 1
IRJCBFDCFXCWGO-UHFFFAOYSA-N Ibotenic acid Natural products OC(=O)C(N)C1=CC(=O)NO1 IRJCBFDCFXCWGO-UHFFFAOYSA-N 0.000 description 1
102000000079 Kainic Acid Receptors Human genes 0.000 description 1
108010069902 Kainic Acid Receptors Proteins 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
125000000174 L-prolyl group Chemical class [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
238000000585 Mann–Whitney U test Methods 0.000 description 1
208000005314 Multi-Infarct Dementia Diseases 0.000 description 1
208000007101 Muscle Cramp Diseases 0.000 description 1
206010029350 Neurotoxicity Diseases 0.000 description 1
241001310793 Podium Species 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
208000028017 Psychotic disease Diseases 0.000 description 1
241000700157 Rattus norvegicus Species 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
208000005392 Spasm Diseases 0.000 description 1
241000906446 Theraps Species 0.000 description 1
206010044221 Toxic encephalopathy Diseases 0.000 description 1
201000004810 Vascular dementia Diseases 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000003570 air Substances 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
229940024606 amino acid Drugs 0.000 description 1
235000001014 amino acid Nutrition 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
230000000202 analgesic effect Effects 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
230000003270 anti-cataleptic effect Effects 0.000 description 1
230000001773 anti-convulsant effect Effects 0.000 description 1
230000003276 anti-hypertensive effect Effects 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
230000000561 anti-psychotic effect Effects 0.000 description 1
239000001961 anticonvulsive agent Substances 0.000 description 1
229960003965 antiepileptics Drugs 0.000 description 1
239000002220 antihypertensive agent Substances 0.000 description 1
230000036506 anxiety Effects 0.000 description 1
239000011260 aqueous acid Substances 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
238000003556 assay Methods 0.000 description 1
AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
238000009395 breeding Methods 0.000 description 1
230000001488 breeding effect Effects 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
229910001424 calcium ion Inorganic materials 0.000 description 1
210000000748 cardiovascular system Anatomy 0.000 description 1
239000000969 carrier Substances 0.000 description 1
238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000003833 cell viability Effects 0.000 description 1
206010008118 cerebral infarction Diseases 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
230000001054 cortical effect Effects 0.000 description 1
239000007822 coupling agent Substances 0.000 description 1
239000006071 cream Substances 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
230000006378 damage Effects 0.000 description 1
238000007405 data analysis Methods 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
230000003412 degenerative effect Effects 0.000 description 1
239000006274 endogenous ligand Substances 0.000 description 1
230000009540 excitatory neurotransmission Effects 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
239000006260 foam Substances 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
239000000174 gluconic acid Substances 0.000 description 1
235000012208 gluconic acid Nutrition 0.000 description 1
239000008187 granular material Substances 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
230000000971 hippocampal effect Effects 0.000 description 1
150000004678 hydrides Chemical class 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
125000002768 hydroxyalkyl group Chemical group 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000002329 infrared spectrum Methods 0.000 description 1
238000013383 initial experiment Methods 0.000 description 1
229940102223 injectable solution Drugs 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000002198 insoluble material Substances 0.000 description 1
239000013067 intermediate product Substances 0.000 description 1
238000011835 investigation Methods 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 1
230000000302 ischemic effect Effects 0.000 description 1
239000012948 isocyanate Substances 0.000 description 1
150000002513 isocyanates Chemical class 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000006210 lotion Substances 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
238000001819 mass spectrum Methods 0.000 description 1
238000005259 measurement Methods 0.000 description 1
239000012528 membrane Substances 0.000 description 1
102000006239 metabotropic receptors Human genes 0.000 description 1
108020004083 metabotropic receptors Proteins 0.000 description 1
239000007758 minimum essential medium Substances 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
239000003158 myorelaxant agent Substances 0.000 description 1
101150006061 neur gene Proteins 0.000 description 1
210000003061 neural cell Anatomy 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
231100000228 neurotoxicity Toxicity 0.000 description 1
230000007135 neurotoxicity Effects 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
239000002674 ointment Substances 0.000 description 1
239000012044 organic layer Substances 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
238000002135 phase contrast microscopy Methods 0.000 description 1
229950010883 phencyclidine Drugs 0.000 description 1
ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
150000002989 phenols Chemical class 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
150000003906 phosphoinositides Chemical class 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
238000007747 plating Methods 0.000 description 1
229920000768 polyamine Polymers 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
230000000506 psychotropic effect Effects 0.000 description 1
238000003653 radioligand binding assay Methods 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
238000011160 research Methods 0.000 description 1
230000007017 scission Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
239000004017 serum-free culture medium Substances 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
229910001415 sodium ion Inorganic materials 0.000 description 1
239000012064 sodium phosphate buffer Substances 0.000 description 1
229940054269 sodium pyruvate Drugs 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
RSIJVJUOQBWMIM-UHFFFAOYSA-L sodium sulfate decahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].[O-]S([O-])(=O)=O RSIJVJUOQBWMIM-UHFFFAOYSA-L 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
239000012265 solid product Substances 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
229940063675 spermine Drugs 0.000 description 1
210000000278 spinal cord Anatomy 0.000 description 1
238000013222 sprague-dawley male rat Methods 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
208000023516 stroke disease Diseases 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000001384 succinic acid Substances 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
230000005062 synaptic transmission Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
238000012353 t test Methods 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
150000003673 urethanes Chemical class 0.000 description 1
229940045145 uridine Drugs 0.000 description 1
230000035899 viability Effects 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Diabetes (AREA)
Toxicology (AREA)
Obesity (AREA)
Hematology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Anesthesiology (AREA)
Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Cosmetics (AREA)
Saccharide Compounds (AREA)
Medicines Containing Plant Substances (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Hydrogenated Pyridines (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

NO963186A 1994-01-31 1996-07-30 Neurobeskyttende kromanforbindelser og farmasöytisk blanding NO309190B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US18947994A	1994-01-31	1994-01-31
PCT/IB1994/000365 WO1995020587A1 (fr)	1994-01-31	1994-11-21	Composes de chromane neuroprotecteurs

Publications (3)

Publication Number	Publication Date
NO963186D0 NO963186D0 (no)	1996-07-30
NO963186L NO963186L (no)	1996-07-30
NO309190B1 true NO309190B1 (no)	2000-12-27

Family

ID=22697514

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO963186A NO309190B1 (no)	1994-01-31	1996-07-30	Neurobeskyttende kromanforbindelser og farmasöytisk blanding

Country Status (27)

Country	Link
US (1)	US5744483A (fr)
EP (1)	EP0741724B1 (fr)
JP (1)	JP2866743B2 (fr)
CN (1)	CN1048247C (fr)
AT (1)	ATE183184T1 (fr)
AU (1)	AU684568B2 (fr)
BR (2)	BR9408506A (fr)
CA (1)	CA2182101C (fr)
CO (1)	CO4230161A1 (fr)
CZ (1)	CZ286757B6 (fr)
DE (1)	DE69420053T2 (fr)
DK (1)	DK0741724T3 (fr)
EG (1)	EG20672A (fr)
ES (1)	ES2134361T3 (fr)
FI (1)	FI113769B (fr)
GR (1)	GR3031356T3 (fr)
HU (1)	HU221633B1 (fr)
IL (1)	IL112415A (fr)
MY (1)	MY111623A (fr)
NO (1)	NO309190B1 (fr)
NZ (1)	NZ275151A (fr)
PE (1)	PE43795A1 (fr)
PL (1)	PL179448B1 (fr)
RU (1)	RU2126404C1 (fr)
TW (1)	TW449591B (fr)
WO (1)	WO1995020587A1 (fr)
ZA (1)	ZA95692B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH11509839A (ja) *	1995-09-15	1999-08-31	ファイザー・インコーポレーテッド	薬剤活性を有するフェノール誘導体
TW498067B (en) *	1996-07-19	2002-08-11	Hoffmann La Roche	4-hydroxy-piperidine derivatives
UA73981C2 (en) *	2000-03-10	2005-10-17	Merck Patent Gmbh	(r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane for treatment of extrapyramidal movement disorders (variants), pharmaceutical composition and kit
PE20020291A1 (es) *	2000-08-21	2002-04-17	Hoffmann La Roche	Profarmacos para ligandos del receptor nmda
ZA200108038B (en) *	2000-10-02	2003-04-01	Pfizer Prod Inc	Prophylactic use of n-methyl-d-asparrate (NMDA) antagonists.
EP1674087A1 (fr)	2000-10-02	2006-06-28	Pfizer Products Inc.	Utilisation prophylactique d'antagonistes des récepteurs du N-méthyl-D-aspartate (NMDA)
SE0100902D0 (sv)	2001-03-15	2001-03-15	Astrazeneca Ab	Compounds
PT1408964E (pt) *	2001-07-26	2007-05-31	Merck Patent Gmbh	Utilização de 2-5-(4-fluorofenil) -3-piridilmetilaminometil-cromano e de seus sais fisiologicamente aceitáveis.
RU2240113C1 (ru) *	2003-01-23	2004-11-20	Государственное образовательное учреждение высшего профессионального образования Московская медицинская академия им. И.М.Сеченова	Способ экстренной медикаментозной помощи при острой травме спинного мозга
US7671072B2 (en) *	2003-11-26	2010-03-02	Pfizer Inc.	Aminopyrazole derivatives as GSK-3 inhibitors
CA2628173A1 (fr)	2005-11-03	2007-05-10	F. Hoffmann-La Roche Ag	Derives d'indolylmaleimide en tant qu'inhibiteurs de proteine kinase
CN102702044A (zh) *	2006-01-20	2012-10-03	先灵公司	作为γ分泌酶抑制剂的碳环和杂环芳基砜化合物
RU2418578C1 (ru) *	2009-12-08	2011-05-20	Новосибирский институт органической химии им. Н.Н. Ворожцова Сибирского отделения Российской академии наук (НИОХ СО РАН)	ПРИМЕНЕНИЕ 4,7-ДИМЕТИЛ-2-(ПРОП-1-ЕНИЛ)-3,4,4a,5,8,8a-ГЕКСАГИДРО-2Н-ХРОМЕН-4,8-ДИОЛА В КАЧЕСТВЕ АНАЛЬГЕЗИРУЮЩЕГО СРЕДСТВА
EP2522647B1 (fr) *	2011-05-10	2014-04-30	DSM IP Assets B.V.	Procédé de séparation d'isomères chiraux de composés de chromane et leurs dérivés et précurseurs

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3294804A (en) *	1961-01-27	1966-12-27	Sterling Drug Inc	1-(3-hydroxy-3-phenylpropyl)-4-phenyl-4-propionoxy-piperidine
FR5733M (fr) *	1966-09-27	1968-01-22
GB1495526A (en) *	1974-05-31	1977-12-21	Beecham Group Ltd	Chroman derivatives
US4016281A (en) *	1975-02-22	1977-04-05	Merck Patent Gesellschaft Mit Beschrankter Haftung	Tetralone and indanone compounds
US4082755A (en) *	1977-02-14	1978-04-04	Janssen Pharmaceutica N.V.	1-[(Diarylmethyl)aminoalkyl]piperidimes
WO1980000152A1 (fr) *	1978-07-03	1980-02-07	Sandoz Ag	Derives d'un 3-aminopropoxy-aryle, leur preparation et utilisation
US4358456A (en) *	1980-05-03	1982-11-09	John Wyeth & Brother Limited	Antipsychotic piperidinomethyl-indole derivatives
DE3045688A1 (de) *	1980-12-04	1982-07-08	C.H. Boehringer Sohn, 6507 Ingelheim	Neue 8-arylalkyl-3-phenyl-3-nortropanole, deren saeureadditionssalze, diese enthaltende arzneimittel und verfahren zu ihrer herstellung
EP0076075B1 (fr) *	1981-09-25	1986-11-20	Beecham Group Plc	Dérivés de benzopyranes pharmacologiquement actifs
EP0093534A1 (fr) *	1982-04-28	1983-11-09	Beecham Group Plc	Chromanols
ES8503669A1 (es) *	1982-07-05	1985-03-01	Erba Farmitalia	Procedimiento para preparar derivados n-imidazolilicos de compuestos biciclicos.
GB8308064D0 (en) *	1983-03-24	1983-05-05	Beecham Group Plc	Active compounds
FR2546166B1 (fr) *	1983-05-19	1985-10-25	Synthelabo	Enantiomeres du erythro (benzyl-4 piperidino)-2 (hydroxy-4 ou benzyloxy-4 phenyl)-1 propanol, leur preparation et leur application en therapeutique
FR2581993B1 (fr) *	1985-05-14	1988-03-18	Synthelabo	Derives de (benzoyl-4 piperidino)-2 phenyl-1 alcanols, leur preparation et leur application en therapeutique
US4957928A (en) *	1986-06-26	1990-09-18	Ciba-Geigy Corporation	Hydrogenated 1-benzooxacycloalkylpyridinecarboxylic acid compounds
US4968678A (en) *	1988-02-19	1990-11-06	Eli Lilly And Company	Tetrazole excitatory amino acid receptor antagonists
FR2640266B2 (fr) *	1988-07-12	1992-07-10	Synthelabo	Derives de (hydroxy-1 piperidinyl-2 alkyl) indolones-2, quinoleinones-2, benzo(b)azepinones-2 et benzimidazolones-2, leur preparation et leur application en therapeutique
US4968878A (en) *	1989-02-07	1990-11-06	Transitions Research Corporation	Dual bumper-light curtain obstacle detection sensor
US4902695A (en) *	1989-02-13	1990-02-20	Eli Lilly And Company	Excitatory amino acid receptor antagonists
SK279476B6 (sk) *	1989-05-17	1998-11-04	Pfizer	Deriváty 2-piperidino a 2-pyrolidino-1-alkanolov a
HU222726B1 (hu) *	1990-02-06	2003-09-29	Pfizer, Inc.,	Piperidinszármazékok, eljárás elżállításukra és az ezeket tartalmazó gyógyszerkészítmények
US5192751A (en) *	1992-07-24	1993-03-09	Eli Lilly And Company	Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence

1994
- 1994-11-21 WO PCT/IB1994/000365 patent/WO1995020587A1/fr not_active Ceased
- 1994-11-21 HU HU9602100A patent/HU221633B1/hu not_active IP Right Cessation
- 1994-11-21 AT AT94931668T patent/ATE183184T1/de not_active IP Right Cessation
- 1994-11-21 CZ CZ19962256A patent/CZ286757B6/cs not_active IP Right Cessation
- 1994-11-21 CN CN94194940A patent/CN1048247C/zh not_active Expired - Fee Related
- 1994-11-21 DK DK94931668T patent/DK0741724T3/da active
- 1994-11-21 AU AU80663/94A patent/AU684568B2/en not_active Ceased
- 1994-11-21 EP EP94931668A patent/EP0741724B1/fr not_active Expired - Lifetime
- 1994-11-21 DE DE69420053T patent/DE69420053T2/de not_active Expired - Fee Related
- 1994-11-21 US US08/687,542 patent/US5744483A/en not_active Expired - Fee Related
- 1994-11-21 ES ES94931668T patent/ES2134361T3/es not_active Expired - Lifetime
- 1994-11-21 RU RU96117381A patent/RU2126404C1/ru not_active IP Right Cessation
- 1994-11-21 NZ NZ275151A patent/NZ275151A/en unknown
- 1994-11-21 BR BR9408506A patent/BR9408506A/pt not_active Application Discontinuation
- 1994-11-21 CA CA002182101A patent/CA2182101C/fr not_active Expired - Fee Related
- 1994-11-21 PL PL94315681A patent/PL179448B1/pl unknown
- 1994-11-21 JP JP7519959A patent/JP2866743B2/ja not_active Expired - Lifetime
- 1994-11-22 TW TW083110873A patent/TW449591B/zh active
1995
- 1995-01-18 PE PE1995259688A patent/PE43795A1/es not_active Application Discontinuation
- 1995-01-23 IL IL11241595A patent/IL112415A/xx not_active IP Right Cessation
- 1995-01-27 CO CO95003001A patent/CO4230161A1/es unknown
- 1995-01-27 MY MYPI95000224A patent/MY111623A/en unknown
- 1995-01-28 EG EG6795A patent/EG20672A/xx active
- 1995-01-30 BR BR9500380A patent/BR9500380A/pt not_active IP Right Cessation
- 1995-01-30 ZA ZA95692A patent/ZA95692B/xx unknown
- 1995-01-30 FI FI950403A patent/FI113769B/fi not_active IP Right Cessation
1996
- 1996-07-30 NO NO963186A patent/NO309190B1/no unknown
1999
- 1999-09-29 GR GR990402449T patent/GR3031356T3/el unknown

Also Published As

Publication number	Publication date
BR9408506A (pt)	1997-08-05
MY111623A (en)	2000-09-27
FI113769B (fi)	2004-06-15
CN1048247C (zh)	2000-01-12
PL179448B1 (pl)	2000-09-29
CZ225696A3 (en)	1997-01-15
AU684568B2 (en)	1997-12-18
ZA95692B (en)	1996-07-30
HU221633B1 (hu)	2002-12-28
FI950403L (fi)	1995-08-01
JP2866743B2 (ja)	1999-03-08
HUT75942A (en)	1997-05-28
NZ275151A (en)	1998-02-26
NO963186D0 (no)	1996-07-30
DE69420053D1 (de)	1999-09-16
RU2126404C1 (ru)	1999-02-20
FI950403A0 (fi)	1995-01-30
DK0741724T3 (da)	1999-12-20
WO1995020587A1 (fr)	1995-08-03
BR9500380A (pt)	1995-10-17
PE43795A1 (es)	1995-12-09
AU8066394A (en)	1995-08-15
PL315681A1 (en)	1996-11-25
IL112415A0 (en)	1995-03-30
DE69420053T2 (de)	1999-11-25
ATE183184T1 (de)	1999-08-15
HU9602100D0 (en)	1996-09-30
GR3031356T3 (en)	2000-01-31
NO963186L (no)	1996-07-30
US5744483A (en)	1998-04-28
CN1142825A (zh)	1997-02-12
CA2182101C (fr)	1999-08-03
IL112415A (en)	1999-07-14
JPH09501698A (ja)	1997-02-18
CO4230161A1 (es)	1995-10-19
ES2134361T3 (es)	1999-10-01
CZ286757B6 (en)	2000-06-14
EP0741724A1 (fr)	1996-11-13
TW449591B (en)	2001-08-11
EG20672A (en)	1999-11-30
CA2182101A1 (fr)	1995-08-03
EP0741724B1 (fr)	1999-08-11

Publication	Publication Date	Title
JP4488891B2 (ja)	2010-06-23	Ｎ−［フェニル（ピペリジン−２−イル）メチル］ベンズアミド誘導体、その製造法、およびその治療用途
US6071932A (en)	2000-06-06	Carbazolypiperines as GABA uptake inhibitors
CA2180238A1 (fr)	1995-07-13	Nouveaux composes heterocycliques
US5843988A (en)	1998-12-01	Cyclopropachromencarboxylic acid derivatives
NO309190B1 (no)	2000-12-27	Neurobeskyttende kromanforbindelser og farmasöytisk blanding
Lalut et al.	2020	Rational design of novel benzisoxazole derivatives with acetylcholinesterase inhibitory and serotoninergic 5-HT4 receptors activities for the treatment of Alzheimer’s disease
JP2007297410A (ja)	2007-11-15	ムスカリンアンタゴニスト
MXPA02000657A (es)	2002-08-30	Derivados de bifenilo, su produccion y uso como inhibidores mtp.
US5436255A (en)	1995-07-25	Method of treating diseases susceptable to treatment by blocking NMDA-receptors
AU2351195A (en)	1996-03-14	Neuroprotective 3-(piperidinyl-1)-chroman-4,7-diol and 1-(4-hydrophenyl)-2-(piperidinyl-1)-alkanol derivatives
JP5296073B2 (ja)	2013-09-25	５−ｈｔ２ａ及びｄ３受容体のデュアルモジュレーターとしてのベンゾイル−ピペリジン誘導体
JP7617134B2 (ja)	2025-01-17	Ｇｐｒ５２アゴニスト活性を有する置換３－フェノキシアゼチジン－１－イル－ピラジン
JP4937347B2 (ja)	2012-05-23	置換フェニルメタノン誘導体
NO300542B1 (no)	1997-06-16	Benzoksazinforbindelser og medikament inneholdende slike
JP3916093B2 (ja)	2007-05-16	光学活性イミダゾリジノン誘導体とその製造方法
MXPA06013941A (es)	2007-12-10	Fenilpiperidinas disustituidas, novedosas, como moduladores de la neurotransmision de dopamina y serotonina.
CZ223896A3 (en)	1997-01-15	Condensation and addition polymers with n,n - bridge bis-tetramethylpiperidinyloxy groupings
Neumeyer et al.	1991	(R)-and (S)-enantiomers of 11-hydroxy-and 10, 11-dihydroxy-N-allylnoraporphine: synthesis and affinity for dopamine receptors in rat brain tissue